Finally, elevated secreted CLU (sCLU) was found in serums from TNBC patients compared to healthy controls, OGX‐011 and/or CRT0066101 treatment resulted in reduced sCLU in serum from TNBC murine models with inhibition of TNBC tumor growth, suggesting potential application of serum sCLU as a blood‐based biomarker for clinical management of TNBC. Here, CLU is linked to neoplasm.